- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Inventiva S.A. Actions Nom. (ADS)/1 o.N. Aktie
Verkaufen
Kaufen
Inventiva S.A. Actions Nom. (ADS)/1 o.N. Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Inventiva S.A. Actions Nom. (ADS)/1 o.N. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Stuttgart | VK | |||||
| Baader | VK | |||||
| gettex | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,84 %
Intraday
-4,08 %
1 Woche
-10,13 %
1 Monat
-47,96 %
Seit Jahresbeginn
-48,01 %
1 Jahr
-82,92 %
3 Jahre
Wikifolio
Passender Service zu Inventiva S.A. Actions Nom. (ADS)/1 o.N.
Webinar zu Inventiva S.A. Actions Nom. (ADS)/1 o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,530-4,750
- Jahrestief / Hoch ($)1,530-4,750
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Inventiva S.A. Actions Nom. (ADS)/1 o.N.
Keine Dividenden verfügbar
Termine von Inventiva S.A. Actions Nom. (ADS)/1 o.N.
Keine aktuellen Termine
Beschreibung
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
